Publications by authors named "T Robak"
JCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial prespecified analysis (median follow-up, 26.
View Article and Find Full Text PDFPredictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk.
Cancers (Basel)
November 2024
Article Synopsis
- Daratumumab (Dara) is the first monoclonal antibody used to treat multiple myeloma (MM), showing effectiveness but also an increased risk of infectious complications (ICs) during treatment.
- A study reviewed data from 139 MM patients treated with Dara from July 2019 to March 2024, finding that 39.6% experienced ICs, primarily pneumonia and upper respiratory infections, with some patients facing severe complications requiring hospitalization.
- Predictive models using various algorithms were developed to identify factors influencing severe ICs, highlighting the importance of hemoglobin levels and performance status in determining patient risk during treatment.
Article Synopsis
- Jayne et al. reveal the molecular details of a specific chromosomal translocation (t(1;6)(p35.3;p25.2)) found in chronic lymphocytic leukaemia patients.
- This translocation involves the IRF4 gene on chromosome 6 and the RCC1 gene on chromosome 1, indicating a fusion between RCC1 and IRF4.
- The study suggests that this chromosomal abnormality could have significant prognostic implications for patients with this type of leukaemia.
Safety considerations for drugs newly approved for treating acute myeloid leukemia.
Expert Opin Drug Saf
November 2024
Article Synopsis
- Acute myeloid leukemia (AML) has a generally poor prognosis due to the age of patients at diagnosis, with treatment options historically limited to intensive chemotherapy or hypomethylating agents.
- Since 2017, nine new drugs have been approved for treating newly-diagnosed AML, expanding treatment possibilities and potentially improving outcomes, especially for older patients.
- However, while these new therapies show promise, they also introduce unique side effects and drug-drug interactions that complicate clinical decision-making.
Introduction: Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adult patients. The landscape of CLL therapy has changed in the last decades with the introduction of antibody-based therapies and novel targeted agents resulting in improved outcomes.
Areas Covered: This article describes the use of monoclonal antibodies, bispecific antibodies and antibody-drug conjugates in the treatment of relapsed and refractory CLL.